Edwards Lifesciences Corp (NYSE:EW) CFO Scott B. Ullem sold 7,500 shares of Edwards Lifesciences stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $233.88, for a total transaction of $1,754,100.00. Following the completion of the transaction, the chief financial officer now owns 17,438 shares in the company, valued at approximately $4,078,399.44. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

NYSE:EW opened at $229.16 on Wednesday. The firm’s fifty day simple moving average is $238.34 and its 200 day simple moving average is $213.31. The company has a current ratio of 3.53, a quick ratio of 2.74 and a debt-to-equity ratio of 0.17. Edwards Lifesciences Corp has a twelve month low of $139.64 and a twelve month high of $247.64. The firm has a market capitalization of $49.84 billion, a price-to-earnings ratio of 48.76, a PEG ratio of 2.89 and a beta of 0.80.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $1.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.19. Edwards Lifesciences had a return on equity of 32.28% and a net margin of 18.64%. The firm had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same period in the prior year, the firm earned $1.07 EPS. The firm’s quarterly revenue was up 20.7% compared to the same quarter last year. On average, analysts predict that Edwards Lifesciences Corp will post 5.6 earnings per share for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Nuveen Asset Management LLC increased its stake in Edwards Lifesciences by 8,278.5% during the 2nd quarter. Nuveen Asset Management LLC now owns 3,951,568 shares of the medical research company’s stock worth $730,013,000 after buying an additional 3,904,405 shares during the period. Marshall Wace North America L.P. grew its stake in shares of Edwards Lifesciences by 394.9% during the second quarter. Marshall Wace North America L.P. now owns 364,492 shares of the medical research company’s stock valued at $67,336,000 after acquiring an additional 290,838 shares in the last quarter. Jennison Associates LLC grew its stake in shares of Edwards Lifesciences by 4.8% during the second quarter. Jennison Associates LLC now owns 6,039,006 shares of the medical research company’s stock valued at $1,115,646,000 after acquiring an additional 275,182 shares in the last quarter. Invesco Ltd. increased its position in shares of Edwards Lifesciences by 16.1% during the second quarter. Invesco Ltd. now owns 1,094,610 shares of the medical research company’s stock worth $202,218,000 after acquiring an additional 151,686 shares during the last quarter. Finally, Morgan Stanley increased its position in shares of Edwards Lifesciences by 16.3% during the second quarter. Morgan Stanley now owns 1,003,510 shares of the medical research company’s stock worth $185,387,000 after acquiring an additional 140,533 shares during the last quarter. 80.88% of the stock is owned by institutional investors.

A number of research firms have recently commented on EW. Morgan Stanley upped their price objective on Edwards Lifesciences from $248.00 to $270.00 and gave the stock an “overweight” rating in a report on Friday, December 6th. Raymond James lifted their target price on Edwards Lifesciences from $255.00 to $263.00 and gave the company an “outperform” rating in a report on Friday, December 6th. Jefferies Financial Group lifted their target price on Edwards Lifesciences from $255.00 to $285.00 and gave the company a “buy” rating in a report on Tuesday, December 3rd. UBS Group boosted their price target on Edwards Lifesciences from $250.00 to $255.00 and gave the company a “neutral” rating in a research report on Friday, December 6th. Finally, Piper Jaffray Companies upped their price target on Edwards Lifesciences from $255.00 to $262.00 and gave the stock an “overweight” rating in a research note on Monday. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $237.72.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Featured Article: Why is Cost of Capital Important?

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.